Heres how Rybelsus works, common side effects, cost considerations, and when you can potentially expect more GLP-1 oral medications to hit the market
The glucagon receptor component is hypothesised to increase energy expenditure and promote fat breakdown (lipolysis), potentially offering additional weight loss benefits
The STEP 8 clinical trials found that once-weekly semaglutide 2.4 mg led to significantly greater weight loss than once-daily liraglutide 3.0 mg at 68 weeks in overweight adults without diabetes
Obesity is not only a major risk factor for the development of T2D but also a risk factor for developing cardiovascular disease, sleep apnea and chronic pulmonary disease, various cancer manifestations, osteoarthritis, reflux disease, gallstones, nonalcoholic steatohepatitis (NASH), and depression (1822)